GRTX Galera Therapeutics, Inc. revenue, earnings and financials
For the quarter ended March 31, 2026, Galera Therapeutics, Inc. reported revenue of n/a, net income of −$1.61M and diluted EPS of −$0.01; for the fiscal year ended December 2025 revenue was n/a.
GRTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$2.54M, net income $149M (margin n/a), EPS $0.64
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$20.2M, net income −$19.0M (margin n/a), EPS −$0.34
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$49.3M, net income −$59.1M (margin n/a), EPS −$1.33
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$51.2M, net income −$62.2M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$73.4M, net income −$80.5M (margin n/a), EPS −$3.12
GRTX quarterly revenue and earnings
- Quarter ended Mar 31, 2026: revenue n/a, net income −$1.61M, EPS −$0.01
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income $153M, EPS $0.66
- Quarter ended Sep 30, 2025: revenue n/a, net income −$1.39M, EPS −$0.01
- Quarter ended Jun 30, 2025: revenue n/a, net income −$1.08M, EPS $0.00
- Quarter ended Mar 31, 2025: revenue n/a, net income −$1.59M, EPS −$0.01
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$4.93M, EPS −$0.09
- Quarter ended Sep 30, 2024: revenue n/a, net income −$5.58M, EPS −$0.10
- Quarter ended Jun 30, 2024: revenue n/a, net income −$4.06M, EPS −$0.07
- Quarter ended Mar 31, 2024: revenue n/a, net income −$4.38M, EPS −$0.08
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.59M, EPS −$0.02
- Quarter ended Sep 30, 2023: revenue n/a, net income −$15.1M, EPS −$0.33
- Quarter ended Jun 30, 2023: revenue n/a, net income −$20.7M, EPS −$0.48
- Quarter ended Mar 31, 2023: revenue n/a, net income −$17.7M, EPS −$0.50
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$16.2M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$16.0M, EPS −$0.60
- Quarter ended Jun 30, 2022: revenue n/a, net income −$14.6M, EPS −$0.54
- Quarter ended Mar 31, 2022: revenue n/a, net income −$15.4M, EPS −$0.58
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$16.8M, EPS −$0.63
- Quarter ended Sep 30, 2021: revenue n/a, net income −$22.6M, EPS −$0.86
- Quarter ended Jun 30, 2021: revenue n/a, net income −$22.4M, EPS −$0.88
GRTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$6.05M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$12.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$44.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$43.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$68.0M, share buybacks n/a
GRTX balance sheet
- Mar 31, 2026: cash $5.50M, total assets $6.16M, total liabilities $1.14M, shareholders' equity $728K
- Dec 31, 2025: cash $6.38M, total assets $7.20M, total liabilities $645K, shareholders' equity $3.97M
- Sep 30, 2025: cash $4.47M, total assets $5.00M, total liabilities $152M, shareholders' equity −$149M
- Jun 30, 2025: cash $5.23M, total assets $6.05M, total liabilities $151M, shareholders' equity −$148M
- Mar 31, 2025: cash $6.69M, total assets $7.66M, total liabilities $152M, shareholders' equity −$147M
- Dec 31, 2024: cash $8.29M, total assets $10.1M, total liabilities $154M, shareholders' equity −$148M
- Sep 30, 2024: cash $8.46M, total assets $8.90M, total liabilities $152M, shareholders' equity −$143M
- Jun 30, 2024: cash $10.7M, total assets $16.4M, total liabilities $154M, shareholders' equity −$138M
Is GRTX profitable?
Yes. Galera Therapeutics, Inc. earned $149M over the last four quarters.
What is GRTX's EPS?
Diluted earnings per share over the last four quarters were $0.64; −$0.01 in the latest quarter.